NYSE: DX

DYNEX CAPITAL INC

CIK 0000826675 · SIC 6798 · Real Estate Investment Trusts

Mega by assets Assets $26.4B as of Sep 13, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

8-K Filed Jul 28, 2026 · Period ending Jul 28, 2026

Dynex Capital expands ATM equity program by 80M shares to 301.3M total authorized

2 material changes detected. Sign up free to read the summary.

424B5 Filed Jul 28, 2026

Dynex Capital prices 99.3M-share offering at $12.64/share, raising $1.26B for investments

4 material changes detected. Sign up free to read the summary.

Partner

Trade DX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed Jul 27, 2026 · Period ending Jun 30, 2026

DX: net income $180.8M. DX portfolio surges 42%; book value +/share on spread tightening; raised

5 material changes detected. Sign up free to read the summary.

8-K Filed Jul 20, 2026 · Period ending Jul 20, 2026

Dynex Capital reports 6.4% Q2 return, raises $391M equity, grows portfolio 11% to $27.6B

5 material changes detected. Sign up free to read the summary.

8-K Filed Jun 16, 2026 · Period ending Jun 15, 2026

Dynex Capital expands board to seven members with appointment of independent director

3 material changes detected. Sign up free to read the summary.

8-K Filed May 22, 2026 · Period ending May 21, 2026

Dynex Capital doubles authorized shares to 720M following shareholder approval

4 material changes detected. Sign up free to read the summary.

8-K Filed Apr 28, 2026 · Period ending Apr 28, 2026

Dynex Capital adds Goldman Sachs, Morgan Stanley to equity sales program

2 material changes detected. Sign up free to read the summary.

424B5 Filed Apr 28, 2026

Summary not yet generated.

10-Q Filed Apr 27, 2026 · Period ending Mar 31, 2026

net income -$80.4M. Dynex scales portfolio 27% to but spread widening drives loss, book value down

5 material changes detected. Sign up free to read the summary.

8-K Filed Apr 21, 2026 · Period ending Apr 16, 2026

Dynex Capital authorizes $350M share buyback program through April 2028

3 material changes detected. Sign up free to read the summary.

8-K Filed Apr 20, 2026 · Period ending Apr 20, 2026

Dynex Capital posts 2.5% loss, raises $442M equity amid portfolio expansion

5 material changes detected. Sign up free to read the summary.

10-K Filed Feb 25, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

424B5 Filed Jan 27, 2026

Dynex Capital launches at-the-market offering of up to 67.35 million shares

5 material changes detected. Sign up free to read the summary.

10-Q Filed Oct 27, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

424B5 Filed Jul 29, 2025

Summary not yet generated.

10-Q Filed Jul 28, 2025 · Period ending Jun 30, 2025

Summary not yet generated.

10-Q Filed Apr 30, 2025 · Period ending Mar 31, 2025

Summary not yet generated.

10-K Filed Feb 28, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

10-Q/A Filed Aug 20, 2014 · Period ending Mar 31, 2014

Summary not yet generated.

424B3 Filed May 13, 2014

Summary not yet generated.

424B3 Filed Apr 19, 2011

Summary not yet generated.

10-K/A Filed Mar 31, 2009 · Period ending Dec 31, 2008

Summary not yet generated.

Latest financial statements

From 10-Q filed Jul 27, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

($s in thousands except per share data)

Description Three months ended June 30, 2026 Three months ended June 30, 2025 Six months ended June 30, 2026 Six months ended June 30, 2025
INTEREST INCOME
Interest income 302,751 111,746 560,141 206,805
Interest expense (208,968) (88,618) (387,104) (166,545)
Net interest income 93,783 23,128 173,037 40,260
GAINS (LOSSES)
Realized gain on sales of investments, net 8,721
Unrealized (loss) gain on investments, net (25,622) 33,652 (277,433) 143,649
Gain (loss) on derivative instruments, net 128,845 (58,093) 233,572 (176,181)
Total gains (losses), net 103,223 (24,441) (35,140) (32,532)
EXPENSES
Compensation and benefits (9,608) (8,013) (24,917) (15,931)
Other general and administrative (5,598) (3,900) (10,768) (7,745)
Other operating expenses (1,007) (380) (1,783) (734)
Total operating expenses (16,213) (12,293) (37,468) (24,410)
Net income (loss) 180,793 (13,606) 100,429 (16,682)
Preferred stock dividends (2,650) (2,680) (5,307) (4,603)
Net income (loss) to common shareholders 178,143 (16,286) 95,122 (21,285)
Other comprehensive income:
Unrealized (loss) gain on available-for-sale investments (865) 4,064 (1,013) 23,454
Total other comprehensive (loss) income (865) 4,064 (1,013) 23,454
Comprehensive income (loss) to common shareholders 177,278 (12,222) 94,109 2,169
Weighted average common shares-basic 222,220,145 113,177,331 211,213,396 101,897,495
Weighted average common shares-diluted 223,603,596 113,177,331 212,479,097 101,897,495
Net income (loss) per common share-basic 0.80 (0.14) 0.45 (0.21)
Net income (loss) per common share-diluted 0.80 (0.14) 0.45 (0.21)

Consolidated Balance Sheets

($s in thousands except per share data)

Description June 30, 2026 (unaudited) December 31, 2025
Cash and cash equivalents 607,562 531,043
Cash collateral posted to counterparties 570,020 399,344
Mortgage-backed securities (including pledged of $23,669,753 and $14,593,470, respectively), at fair value 25,066,198 16,306,988
Due from counterparties 53,446 17,425
Derivative assets 8,441 10,498
Accrued interest receivable 104,272 67,940
Other assets 9,663 8,940
Total assets 26,419,602 17,342,178
LIABILITIES AND SHAREHOLDERS’ EQUITY
Liabilities:
Repurchase agreements 22,644,742 13,904,231
Due to counterparties 380,947 811,656
Derivative liabilities 9,117 4,830
Cash collateral posted by counterparties 15,500 8,373
Accrued interest payable 135,194 95,196
Dividends payable 46,943 37,171
Other liabilities 12,092 18,577
Total liabilities 23,244,535 14,880,034
Shareholders’ equity:
Preferred stock, par value $0.01 per share; 50,000,000 shares authorized; 4,460,000 and 4,460,000 shares issued and outstanding, respectively ($111,500 and $111,500 aggregate liquidation preference, respectively) 107,843 107,843
Common stock, par value $0.01 per share, 720,000,000 and 360,000,000 shares authorized, respectively; 237,414,259 and 174,814,912 shares issued and outstanding, respectively 2,374 1,748
Additional paid-in capital 3,760,123 2,921,551
Accumulated other comprehensive loss (128,074) (127,061)
Accumulated deficit (567,199) (441,937)
Total shareholders’ equity 3,175,067 2,462,144
Total liabilities and shareholders’ equity 26,419,602 17,342,178

Consolidated Statements of Cash Flows (Unaudited)

($s in thousands)

Description Six months ended June 30, 2026 Six months ended June 30, 2025
Operating activities:
Net income (loss) 100,429 (16,682)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Realized gain on sales of investments, net (8,721)
Unrealized loss (gain) on investments, net 277,433 (143,649)
(Gain) loss on derivative instruments, net (233,572) 176,181
Amortization of investment premiums, net 10,538 14,362
Other amortization and depreciation 1,147 1,012
Share-based compensation expense 10,493 5,515
Increase in accrued interest receivable (36,332) (10,468)
Increase in accrued interest payable 39,998 16,183
Change in other assets and liabilities, net (7,416) (4,212)
Net cash provided by operating activities 153,997 38,242
Investing activities:
Purchases of investments (11,208,638) (2,629,521)
Principal payments received on trading securities 1,067,688 307,342
Principal payments received on available-for-sale investments 37,422 80,416
Proceeds from sales of trading securities 633,301
Principal payments received on mortgage loans held for investment 25 124
Net receipts (payments) on derivative instruments 202,939 (201,106)
Increase in cash collateral posted by counterparties 7,127 29,323
Net cash used in investing activities (9,260,136) (2,413,422)
Financing activities:
Borrowings under repurchase agreements 110,509,461 57,143,834
Repayments of repurchase agreement borrowings (101,768,950) (55,106,811)
Proceeds from issuance of common stock 833,006 521,807
Cash paid for stock issuance costs (120)
Payments related to tax withholding for share-based compensation (4,144) (1,181)
Dividends paid (215,919) (98,171)
Net cash provided by financing activities 9,353,334 2,459,478
Net increase in cash, including cash posted to counterparties 247,195 84,298
Cash including cash collateral posted to counterparties at beginning of period 930,387 621,539
Cash including cash collateral posted to counterparties at end of period 1,177,582 705,837
Supplemental Disclosure of Cash Activity:
Cash paid for interest on repurchase agreements 347,106 150,362
Noncash Investing Activities:
Payable for investments pending settlement 379,447 937,216

Amounts as printed on the EDGAR/iXBRL face — ($s in thousands except per share data); ($s in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

View AI report for this filing